Freitas-Junior Lucio H, Chatelain Eric, Kim Helena Andrade, Siqueira-Neto Jair L
Center for Neglected Diseases Drug Discovery (CND3), Institut Pasteur Korea, Seongnam-si, Gyeonggi-do, South Korea.
Drugs for Neglected Diseases initiative (DND i ), 15 Chemin Louis Dunant, Geneva 1202, Switzerland.
Int J Parasitol Drugs Drug Resist. 2012 Jan 28;2:11-9. doi: 10.1016/j.ijpddr.2012.01.003. eCollection 2012 Dec.
Leishmaniasis is one of the most neglected tropical disease in terms of drug discovery and development. Most antileishmanial drugs are highly toxic, present resistance issues or require hospitalization, being therefore not adequate to the field. Recently improvements have been achieved by combination therapy, reducing the time and cost of treatment. Nonetheless, new drugs are still urgently needed. In this review, we describe the current visceral leishmaniasis (VL) treatments and their limitations. We also discuss the new strategies in the drug discovery field including the development and implementation of high-throughput screening (HTS) assays and the joint efforts of international teams to deliver clinical candidates.
就药物研发而言，利什曼病是最被忽视的热带疾病之一。大多数抗利什曼原虫药物毒性很强，存在耐药性问题或需要住院治疗，因此不适用于现场治疗。最近，联合疗法取得了进展，减少了治疗时间和成本。尽管如此，仍然迫切需要新药。在这篇综述中，我们描述了当前内脏利什曼病（VL）的治疗方法及其局限性。我们还讨论了药物研发领域的新策略，包括高通量筛选（HTS）分析方法的开发和应用，以及国际团队为推出临床候选药物所做的共同努力。
